| Code | 1287C | ||||||||||
| MA number | 44/0433/16-S | ||||||||||
| Product Form: | plc ifc 1x25 mg (liek.inj.skl.) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Fresenius Kabi s.r.o., Czechia | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Intravenous use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 28.09.2016 |
| SPC: |
SPC_Bendamustine Kabi 2,5 mg_ml_06.2024.pdf
|
| PIL: |
PIL_Bendamustine Kabi 2,5 mg_ml_06.2024.pdf
|
| Safety feature | Yes |
| Data update: | 04.05.2022 |
